Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives Read more about Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium Read more about Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium
CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium Read more about Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid Read more about Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update Read more about Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa Read more about Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)